Observational Study of Oral Cariprazine Capsules to Assess Change in Disease Activity in Adult Participants With Bipolar I Disorder

Bipolar I disorder (BP-I) is a common, chronic, and disabling mental illness with significant morbidity and mortality defined by episodes of mania and depression (or symptoms of both at once, known as mixed features). This prospective, observational study will examine effectiveness, functioning and quality of life outcomes in adult patients with BP-I experiencing a major depressive episode (with or without mixed features) requiring treatment and initiating treatment with cariprazine. It will examine outcomes of cariprazine treatment in a real-world setting in patients with BP-I commonly seen in clinical practices.

Cariprazine (Vraylar) is a medication indicated in the United States and Canada to treat adult patients experiencing manic, mixed or depressive episodes associated with BP-I. This study plans to enroll approximately 170 adult patients with BP-I from the United States and Canada. Cariprazine should be prescribed by the physician under the usual and customary practice of physician prescription. The decision to initiate treatment with cariprazine should be made prior to, and independently from, the patient's decision to participate in the study.

Participants will receive cariprazine as prescribed by their physician. Observational data will be collected during visits which should align to routine standard of care for a duration of up to 24 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bipolar I Disorder

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chatham-Kent Clinical Trials /ID# 262414, Chatham, Ontario, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Have a physician-confirmed diagnosis of BP-I, with or without comorbidities.
Prescribed cariprazine as part of routine clinical practice with the intention of treating as per the approved market label, respective country indications, and by the physician under usual and customary practice of physician prescription.
Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score >= 20 at baseline.
Have a Functioning Assessment Short Test (FAST) score >= 21 at baseline.
Naïve to cariprazine in the current major depressive episode.

Exclusion criteria

Have a medical or psychiatric condition, or planned surgical procedure, which will interfere with study participation, as judged by the investigator.
Have a known contraindication to cariprazine including any of the following:

Hypersensitivity to cariprazine or any ingredient in the formulation
For all sites, concomitant use of strong cytochrome P450 (CYP) 3A4 inhibitors and inducers
For Canadian sites, as per country label, concomitant use of moderate CYP 3A4 inhibitors and inducers
Current major depressive episode duration > 12 months.

Treatment and study plan

Primary outcomes

Change From Baseline on Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score

Time frame: Up to Week 12

MADRS is a 10-item questionnaire that is rated by investigators to assess changes in depression symptoms over the past week. The individual items (apparent sadness, reported sadness, feelings of tension, reduced appetite, reduced sleep, lassitude, concentration difficulties, pessimistic thoughts, inability to feel emotions, and suicidal thoughts) are scored from 0 (no symptoms) to 6 (maximum severity) and summed for the total score (range 0 to 60). Higher scores indicate more severe depression.

Secondary outcomes

Change From Baseline on Functioning Assessment Short Test (FAST) Total Score

Time frame: Up to Week 12

The FAST is comprised of 24 items and assesses disability or impairment in 6 domains: autonomy, occupational functioning, financial issues, interpersonal relationships, cognitive functioning, and leisure time. FAST is administered by the investigator as an interview. Items are rated using a 4-point scale, from 0 (no difficulty) to 3 (severe difficulty) then summed for a total score. Higher scores indicate more severe impairment.

Sponsors and collaborators

Lead sponsor

AbbVie

Industry

Registry information

Official study title

Cariprazine Real-world Use in Bipolar I Disorder: Effectiveness, Functioning, Quality of Life, and Tolerability

Acronym: CReW BP-I

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Feb 13, 2024
Registry last updated: Feb 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed